글로벌 혈장 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

혈장 시장 분석

혈장은 피브리노겐, 프로테아제 억제제, 응고 인자, 알부민 , 면역글로불린 등 100개 이상의 다양한 단백질을 보유하고 있는 것으로 알려져 있습니다 . 이들은 혈압을 유지하고 칼륨과 나트륨을 포함한 미네랄을 교환하는 데 중요한 역할을 합니다.

세계 혈장 시장 규모

글로벌 혈장 시장 규모는 2023년에 3,161만 달러로 평가되었으며, 2031년까지 707억 7,000만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 10.60%입니다.

보고 범위 및 시장 세분화       

Blood Plasma Market Definition

Plasma refers to a straw coloured clear liquid component of the blood that is protein salt solution. Red blood cells, white blood cells, and platelets are the three types of blood cells that are suspended in the plasma. The blood plasma product have numerous advantages including the coagulation of blood, and defense, among others.

Blood Plasma Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints and challenges. All of this is discussed in detail as below:

Drivers

• Approval for Blood Plasma Products

The increase in number of approval for blood plasma products across the globe acts as one of the major factor driving the growth of blood plasma market. The rise in clinical studies for evaluating safety and efficiency of a wide range of therapeutic drugs have a positive impact on the market.

• Prevalence of Blood Disorders

The rise in prevalence of blood and disorders, such as malignancies and leukemia and types of lymphoma, sickle-cell anemia and haemophilia, among others accelerate the market growth.

• Increase In Mergers and Acquisitions

The increase in the number of mergers and acquisitions among manufacturers and research organizations to provide efficient medical care to patients and generate significant revenues by their sales options results in the expansion of the market.

Additionally, development in technology, large patient base and superior technology, increase in demand for effective therapies and surge in healthcare expenditure positively affect the blood plasma market.

Opportunities

Furthermore, research and development activities to develop advanced plasma derived product extends profitable opportunities to the market players in the forecast period of 2024 to 2031. Also, strategic manufacturing and distribution of plasma products will escalate the growth of blood plasma market.

Restraints/Challenges

On the other hand, side effects caused due to use of blood plasma derivative such as dizziness, shortness in breath, allergic condition, dizziness and, fast heartbeats are expected to obstruct the market growth. The stringent regulatory policies for the approval are projected to challenge the blood plasma market in the forecast period of 2024-2031.

This blood plasma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on blood plasma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Death of more than 60,000 Americans anually have been reported due to hemorrhaging, or blood loss. Also, hemophilia A affects 1 in 5,000 male births each year in the U.S. according to the Centers for Disease Control and Prevention.

The blood plasma market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Blood Plasma Market

The COVID-19 outbreak had a positive impact on growth of the blood plasma market. The COVID-19 pandemic stressed healthcare systems across the globe. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for convalescent plasma for treating hospitalized patients with COVID-19 in August 2020. The antibodies or plasma are collected from individuals who have recovered from COVID-19 to use for the patients suffering from COVID-19.

Blood Plasma Market

The blood plasma market is segmented on the basis of type, mode of delivery, therapeutic indication, application and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Hyperimmune Globulin
• Albumin
• Factor Viii
• Factor Ix
• Immunoglobulin
• Others

Mode of Delivery

• Infusion Solutions
• Gels
• Sprays
• Biomedical Sealants

Therapeutic Indication

• Immunology
• Oncology
• Pulmonology
• Rheumatology
• Transplantation
• Neurology
• Hematology
• Other

Application

• Hypogammaglobulinemia
• Immunodeficiency Diseases
• Hemophilia
• Von Willebrand's Disease (Vwd)
• Others

End User

• Hospitals
• Clinics
• Other

Pipeline Analysis

Allergan, AbbVie Inc., GALDERMA, Evolus, Inc., Revance, HUGEL, Inc., Ipsen Pharma,USWM, LLC., Sun Pharmaceutical Industries Ltd., Pfizer Inc., GlaxoSmithKline plc, ., among others are some of the manufacturers involved with the development of plasma products.

Blood Plasma Market Regional Analysis

The blood plasma market is analysed and market size insights and trends are provided by country, type, mode of delivery, therapeutic indication, application and end user as referenced above.

The countries covered in the blood plasma market report are U.S., Canada and Mexico in North America, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the blood plasma market due to the rise in the inclination towards prophylaxis treatment within the region.

Asia-Pacific is expected to witness high growth during the forecast period of 2024 to 2031 because of the early diagnosis of the diseases in countries in the region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Blood Plasma Market Share

The blood plasma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to blood plasma market.

Blood Plasma Market Leaders Operating in the Market Are:

• Allergan (Ireland)
• AbbVie Inc. (US)
• GALDERMA (Switzerland)
• Evolus, Inc. (US)
• Revance (US)
• HUGEL, Inc. (South Korea)
• Ipsen Pharma (France)
• USWM, LLC. (US)
• Sun Pharmaceutical Industries Ltd. (India)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Merz Pharma (Germany)
• Medytox (South Korea)
• Smith+Nephew (US)
• Sanofi (France)
• Novartis AG (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• LGM Pharma. (US)
• Lannett (US)
• NorthStar Rx LLC (US)
• Par Pharmaceutical (US)

Latest Developments in Blood Plasma Market

• 유럽 ​​혈액 연합(EBA)은 2020년 5월 DG CNECT, DG DIGIT 및 DG SANTE로 구성된 유럽 위원회와 손을 잡았습니다. 이 파트너십은 COVID-19 회복기 혈장 요법에 대한 데이터를 수집하는 EU 전역의 오픈 액세스 플랫폼을 구축하고 관리하는 것을 목표로 합니다.

SKU-24740